Details for Patent: 7,700,128

Which drugs does patent 7,700,128 protect, and when does it expire?

Patent 7,700,128 protects DUETACT and is included in one NDA.

This patent has thirty-four patent family members in twenty-eight countries.

Summary for Patent: 7,700,128

Title:	Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
Abstract:	A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue, which comprises an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided.
Inventor(s):	Doken; Kazuhiro (Osaka, JP), Kawano; Tetsuya (Osaka, JP), Koyama; Hiroyoshi (Osaka, JP), Hamaguchi; Naoru (Osaka, JP)
Assignee:	Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:	10/544,581
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,700,128

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	AB	RX	Yes	Yes			Y
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	AB	RX	Yes	No			Y

Foreign Priority and PCT Information for Patent: 7,700,128

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2003-371679	Oct 31, 2003

PCT Information
PCT Filed	October 21, 2004	PCT Application Number:	PCT/JP2004/015958
PCT Publication Date:	May 12, 2005	PCT Publication Number:	WO2005/041962

International Family Members for US Patent 7,700,128

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	046210
Australia	2004285354
Brazil	PI0414979
Canada	2540225
China	1874774
Cyprus	1117176